Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial.

dc.contributor.author

Boorjian, Stephen A

dc.contributor.author

Alemozaffar, Mehrdad

dc.contributor.author

Konety, Badrinath R

dc.contributor.author

Shore, Neal D

dc.contributor.author

Gomella, Leonard G

dc.contributor.author

Kamat, Ashish M

dc.contributor.author

Bivalacqua, Trinity J

dc.contributor.author

Montgomery, Jeffrey S

dc.contributor.author

Lerner, Seth P

dc.contributor.author

Busby, Joseph E

dc.contributor.author

Poch, Michael

dc.contributor.author

Crispen, Paul L

dc.contributor.author

Steinberg, Gary D

dc.contributor.author

Schuckman, Anne K

dc.contributor.author

Downs, Tracy M

dc.contributor.author

Svatek, Robert S

dc.contributor.author

Mashni, Joseph

dc.contributor.author

Lane, Brian R

dc.contributor.author

Guzzo, Thomas J

dc.contributor.author

Bratslavsky, Gennady

dc.contributor.author

Karsh, Lawrence I

dc.contributor.author

Woods, Michael E

dc.contributor.author

Brown, Gordon

dc.contributor.author

Canter, Daniel

dc.contributor.author

Luchey, Adam

dc.contributor.author

Lotan, Yair

dc.contributor.author

Krupski, Tracey

dc.contributor.author

Inman, Brant A

dc.contributor.author

Williams, Michael B

dc.contributor.author

Cookson, Michael S

dc.contributor.author

Keegan, Kirk A

dc.contributor.author

Andriole, Gerald L

dc.contributor.author

Sankin, Alexander I

dc.contributor.author

Boyd, Alan

dc.contributor.author

O'Donnell, Michael A

dc.contributor.author

Sawutz, David

dc.contributor.author

Philipson, Richard

dc.contributor.author

Coll, Ruth

dc.contributor.author

Narayan, Vikram M

dc.contributor.author

Treasure, F Peter

dc.contributor.author

Yla-Herttuala, Seppo

dc.contributor.author

Parker, Nigel R

dc.contributor.author

Dinney, Colin PN

dc.date.accessioned

2021-01-01T20:56:15Z

dc.date.available

2021-01-01T20:56:15Z

dc.date.issued

2020-11-27

dc.date.updated

2021-01-01T20:56:14Z

dc.description.abstract

Background

BCG is the most effective therapy for high-risk non-muscle-invasive bladder cancer. Nadofaragene firadenovec (also known as rAd-IFNa/Syn3) is a replication-deficient recombinant adenovirus that delivers human interferon alfa-2b cDNA into the bladder epithelium, and a novel intravesical therapy for BCG-unresponsive non-muscle-invasive bladder cancer. We aimed to evaluate its efficacy in patients with BCG-unresponsive non-muscle-invasive bladder cancer.

Methods

In this phase 3, multicentre, open-label, repeat-dose study done in 33 centres (hospitals and clinics) in the USA, we recruited patients aged 18 years or older, with BCG-unresponsive non-muscle-invasive bladder cancer and an Eastern Cooperative Oncology Group status of 2 or less. Patients were excluded if they had upper urinary tract disease, urothelial carcinoma within the prostatic urethra, lymphovascular invasion, micropapillary disease, or hydronephrosis. Eligible patients received a single intravesical 75 mL dose of nadofaragene firadenovec (3 × 1011 viral particles per mL). Repeat dosing at months 3, 6, and 9 was done in the absence of high-grade recurrence. The primary endpoint was complete response at any time in patients with carcinoma in situ (with or without a high-grade Ta or T1 tumour). The null hypothesis specified a complete response rate of less than 27% in this cohort. Efficacy analyses were done on the per-protocol population, to include only patients strictly meeting the BCG-unresponsive definition. Safety analyses were done in all patients who received at least one dose of treatment. The study is ongoing, with a planned 4-year treatment and monitoring phase. This study is registered with ClinicalTrials.gov, NCT02773849.

Findings

Between Sept 19, 2016, and May 24, 2019, 198 patients were assessed for eligibility. 41 patients were excluded, and 157 were enrolled and received at least one dose of the study drug. Six patients did not meet the definition of BCG-unresponsive non-muscle-invasive bladder cancer and were therefore excluded from efficacy analyses; the remaining 151 patients were included in the per-protocol efficacy analyses. 55 (53·4%) of 103 patients with carcinoma in situ (with or without a high-grade Ta or T1 tumour) had a complete response within 3 months of the first dose and this response was maintained in 25 (45·5%) of 55 patients at 12 months. Micturition urgency was the most common grade 3-4 study drug-related adverse event (two [1%] of 157 patients, both grade 3), and there were no treatment-related deaths.

Interpretation

Intravesical nadofaragene firadenovec was efficacious, with a favourable benefit:risk ratio, in patients with BCG-unresponsive non-muscle-invasive bladder cancer. This represents a novel treatment option in a therapeutically challenging disease state.

Funding

FKD Therapies Oy.
dc.identifier

S1470-2045(20)30540-4

dc.identifier.issn

1470-2045

dc.identifier.issn

1474-5488

dc.identifier.uri

https://hdl.handle.net/10161/21958

dc.language

eng

dc.publisher

Elsevier BV

dc.relation.ispartof

The Lancet. Oncology

dc.relation.isversionof

10.1016/s1470-2045(20)30540-4

dc.title

Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial.

dc.type

Journal article

duke.contributor.orcid

Inman, Brant A|0000-0002-6060-4485

pubs.organisational-group

School of Medicine

pubs.organisational-group

Duke Cancer Institute

pubs.organisational-group

Surgery, Urology

pubs.organisational-group

Duke

pubs.organisational-group

Institutes and Centers

pubs.organisational-group

Surgery

pubs.organisational-group

Clinical Science Departments

pubs.publication-status

Published

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Boorjian LancetOncol 2020.pdf
Size:
800.6 KB
Format:
Adobe Portable Document Format